IP Library › Patent Application 14903610
Patent Application
App. No. 14/903,610

Production of Glycoproteins Having Increased N-Glycosylation Site Occupancy

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/903,610
Abstract

The present disclosure relates to compositions and methods useful for the production of heterologous proteins with increased N-glycosylation site occupancy in filamentous fungal cells, such as Trichoderma cells. More specifically, the invention provides a filamentous fungal cell comprising i. one or more mutation that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s), ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase, and iii. a polynucleotide encoding a heterologous glycoprotein, wherein said catalytic subunit of oligosaccharyl transferase is selected from Leishmania oligosaccharyl transferase catalytic subunits.

Claims (50)

1 . A filamentous fungal cell comprising

i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s),

ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase, and

iii. a polynucleotide encoding a heterologous glycoprotein,

wherein said catalytic subunit of oligosaccharyl transferase is selected from Leishmania oligosaccharyl transferase catalytic subunits.

2 . The filamentous fungal cell of claim 1 , wherein the filamentous fungal cell is a Trichoderma, Neurospora, Myceliophtora, Chrysosporium, Aspergillus , or Fusarium cell.

3 . The filamentous fungal cell of claim 1 , wherein said polynucleotide encoding the heterologous catalytic subunit of oliogaccharyl transferase comprises a nucleic acid selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 9, SEQ ID NO: 88 and SEQ ID NO: 90 or a polynucleotide encoding a functional variant polypeptide having at least 50%, at least 60%, at least 70% identity, at least 80% identity, at least 90% identity, or at least 95% identity with SEQ ID NO: 1, SEQ II) NO: 8, SEQ II) NO: 89 or SEQ II) NO:91, said functional variant polypeptide having oligosaccharyltransferase activity.

4 . The filamentous fungal cell of claim 1 , wherein the N-glycosylation site occupancy of the heterologous glycoprotein is at least 95% and Man3, Man5, GO, G1 and/or G2 glycoforms represent at least 50% of total neutral N-glycans of the heterologous glycoprotein.

5 . The filamentous fungal cell of claim 1 , wherein said cell is a Trichoderma cell and said cell comprises mutations that reduce or eliminate the activity of

the three endogenous proteases pep1, tsp1, and slp1;

the three endogenous proteases gap1, slp1, and pep1;

the three endogenous proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, pep8, pep9, pep11, pep12, tsp1, slp1, slp2, slp3, slp7, gap1 and gap2;

three to six proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, tsp1, slp1, slp2, slp3, gap1 and gap2; or,

seven to ten proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, pep7, pep8, tsp1, slp1, slp2, slp3, slp5, slp6, slp7, slp8, tpp1, gap1 and gap2.

6 . The filamentous fungal cell of claim 1 , wherein the fungal cell further comprises a mutation in the gene encoding ALG3 that reduces or eliminates the corresponding ALG3 expression compared to the level of expression of ALG3 gene in a parental cell which does not have such mutation.

7 . The filamentous fungal cell of any one of the preceding claim 1 , further comprising a polynucleotide encoding an N-acetylglucosaminyltransferase catalytic domain and an N-acetylglucosaminyltransferase II catalytic domain.

8 . The filamentous fungal cell of claim 1 , further comprising one or more polynucleotides encoding a polypeptide selected from the group consisting of:

i. α1, 2 mannosidase;

ii. N-acetylglucosaminyltransferase I catalytic domain;

iii. α-mannosidase II;

iv. N-acetylglucosaminyltransferase II catalytic domain;

v. β1,4 galactosyltransferase; and;

vi. fucosyltransferase.

9 . A method of producing a heterologous glycoprotein, or antibody composition, with increased N-glycosylation site occupancy, comprising

a) providing a filamentous fungal cell having a Leishmania STT3D gene encoding a catalytic subunit of oligosaccharyl transferase, or a functional variant thereof, and a polynucleotide encoding said heterologous glycoprotein or antibody,

b) culturing the cell under appropriate conditions for expression of the STT3D gene or its functional variant, or said functional variant, and the production of the heterologous glycoprotein; and,

recovering and, optionally, purifying the heterologous glycoprotein.

10 . The method of claim 9 , wherein said filamentous fungal host cell comprises one or more mutation(s) that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation.

11 . The method of claim 9 , wherein said filamentous fungal host cell comprises:

i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s),

ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase selected from Leishmania oligosaccharyl transferase catalytic subunits, and

iii. a polynucleotide encoding a heterologous glycoprotein.

12 . The method of claim 9 , wherein said Leishmania STT3D gene encoding a catalytic subunit of oligosaccharyl transferase comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:9, SEQ ID NO: 88 and SEQ ID NO: 90, or a polynucleotide encoding a functional variant polypeptide having at least 50%, at least 60%, at least 70% identity, at least 80% identity, at least 90% identity, or at least 95% identity with SEQ ID NO:1, SEQ ID NO:8, SEQ ID NO: 89 or SEQ ID NO: 91, said functional variant polypeptide having oligosaccharyltransferase activity.

13 . The method of claim 9 , wherein N-glycosylation site occupancy of the produced glycoprotein composition is at least 80%.

14 . A glycoprotein or antibody composition obtainable by the method of claim 9 .

15 . The glycoprotein or antibody composition according to claim 14 ,

wherein said antibody composition further comprises, as a major glycoform, either:

i. Manα3[Manα6(Manα3)Manα6]Manβ4GlcNAβ4GlcNAc (Man5 glycoform);

ii. GlcNAcβ2Manα3[Manα6(Manα3)Manα6]Manβ4GlcNAβ4GlcNAc (GlcNAcMan5 glycoform);

iii Manα6(Manα3)Manβ4GlcNAβ4GlcNAc (Man3 glycoform);

iv. Manα6(GlcNAcβ2Manα3)Manβ4GlcNAβ4GlcNAc (GlcNAcMan3 glycoform); or,

v. complex type N-glycans selected from the G0, G1, and G2 glycoforms.

16 . The filamentous fungal cell of claim 2 , wherein said polynucleotide encoding the heterologous catalytic subunit of oliogaccharyl transferase comprises a nucleic acid selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 9, SEQ ID NO: 88 and SEQ ID NO: 90 or a polynucleotide encoding a functional variant polypeptide having at least 50%, at least 60%, at least 70% identity, at least 80% identity, at least 90% identity, or at least 95% identity with SEQ II) NO: 1, SEQ II) NO: 8, SEQ II) NO: 89 or SEQ II) NO:91, said functional variant polypeptide having oligosaccharyltransferase activity.

17 . The filamentous fungal cell of claim 2 , wherein the N-glycosylation site occupancy of the heterologous glycoprotein is at least 95% and Man3, Man5, GO, G1 and/or G2 glycoforms represent at least 50% of total neutral N-glycans of the heterologous glycoprotein.

18 . The filamentous fungal cell of claim 2 , wherein the N-glycosylation site occupancy of the heterologous glycoprotein is at least 95% and Man3, Man5, GO, G1 and/or G2 glycoforms represent at least 50% of total neutral N-glycans of the heterologous glycoprotein.

19 . The filamentous fungal cell of claim 3 , wherein the N-glycosylation site occupancy of the heterologous glycoprotein is at least 95% and Man3, Man5, GO, G1 and/or G2 glycoforms represent at least 50% of total neutral N-glycans of the heterologous glycoprotein.

20 . The method of claim 10 , wherein said filamentous fungal host cell comprises:

i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s),

ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase selected from Leishmania oligosaccharyl transferase catalytic subunits, and

iii. a polynucleotide encoding a heterologous glycoprotein.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: NOVARTIS AG; GLYKOS FINLAND OY
To: GLYKOS FINLAND OY
Reel/Frame 056061/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2017
From: LANDOWSKI, CHRISTOPHER; SALOHEIMO, MARKKU
To: TEKNOLOGIAN TUTKIMUSKESKUS VTT
Reel/Frame 040868/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2017
From: TEKNOLOGIAN TUTKIMUSKESKUS VTT
To: GLYKOS FINLAND OY
Reel/Frame 040868/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2017
From: GLYKOS FINLAND OY
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; GLYKOS FINLAND OY
Reel/Frame 040868/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2017
From: NATUNEN, JARI
To: GLYKOS FINLAND OY
Reel/Frame 041275/0496 →